Stocks · News reference
Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacyAmong patients surveyed in the study, 94% of those open to a new systemic therapy expressed
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings aloneFRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/ -- Castle Biosciences,
New 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing test volumes and long-term growthFRIENDSWOOD, Texas, Sept. 22, 2026 /PRNewswire/ -- Castle Biosciences,